BR112021026551A2 - Ativador de função mitocondrial - Google Patents

Ativador de função mitocondrial

Info

Publication number
BR112021026551A2
BR112021026551A2 BR112021026551A BR112021026551A BR112021026551A2 BR 112021026551 A2 BR112021026551 A2 BR 112021026551A2 BR 112021026551 A BR112021026551 A BR 112021026551A BR 112021026551 A BR112021026551 A BR 112021026551A BR 112021026551 A2 BR112021026551 A2 BR 112021026551A2
Authority
BR
Brazil
Prior art keywords
mitochondrial function
function activator
activator
present
pharmaceutical agent
Prior art date
Application number
BR112021026551A
Other languages
English (en)
Inventor
Tetsuji Noda
Tomotsune ONAGA
Yoshinori Katakura
Original Assignee
Univ Kyushu Nat Univ Corp
Yuki Gosei Yakuhin Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kyushu Nat Univ Corp, Yuki Gosei Yakuhin Kogyo Kk filed Critical Univ Kyushu Nat Univ Corp
Publication of BR112021026551A2 publication Critical patent/BR112021026551A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

ativador de função mitocondrial. o objetivo da presente invenção consiste em fornecer um agente farmacêutico que ativa função mitocondrial, particularmente, um agente farmacêutico não dispendioso. o problema pode ser resolvido por um ativador de função mitocondrial da presente invenção, que compreende ß-alanina ou glicina, ou um sal das mesmas.
BR112021026551A 2019-06-28 2020-06-16 Ativador de função mitocondrial BR112021026551A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019121874 2019-06-28
PCT/JP2020/023600 WO2020262114A1 (ja) 2019-06-28 2020-06-16 ミトコンドリア機能活性化剤

Publications (1)

Publication Number Publication Date
BR112021026551A2 true BR112021026551A2 (pt) 2022-02-15

Family

ID=74060145

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021026551A BR112021026551A2 (pt) 2019-06-28 2020-06-16 Ativador de função mitocondrial

Country Status (6)

Country Link
US (1) US20220313639A1 (pt)
EP (1) EP3991790A4 (pt)
JP (1) JPWO2020262114A1 (pt)
CN (1) CN114302718A (pt)
BR (1) BR112021026551A2 (pt)
WO (1) WO2020262114A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023106325A1 (ja) * 2021-12-07 2023-06-15 有機合成薬品工業株式会社 β－アラニン吸収抑制剤
JP7319445B1 (ja) 2022-11-11 2023-08-01 ザ コカ・コーラ カンパニー 飲料、及び飲料の塩味を改善する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1883406T3 (en) * 2005-05-23 2016-08-15 Natural Alternatives Int Inc COMPOSITIONS AND PROCEDURES FOR LONG-TERM RELEASE OF BETA-ALANINE
JP6199579B2 (ja) 2013-02-28 2017-09-20 三宅　正治 ミトコンドリア機能回復促進剤
JP6478307B2 (ja) 2013-11-19 2019-03-06 国立大学法人九州大学 ミトコンドリア活性化剤
MX2017015236A (es) * 2015-05-28 2018-11-09 Baylor College Medicine Beneficios de la suplementacion con n-acetilcisteina y glicina para mejorar los niveles de glutation.
WO2017102738A1 (en) * 2015-12-13 2017-06-22 Verburgh Kris Methods and compositions to slow down aging in cells and organisms

Also Published As

Publication number Publication date
US20220313639A1 (en) 2022-10-06
CN114302718A (zh) 2022-04-08
EP3991790A4 (en) 2023-10-25
EP3991790A1 (en) 2022-05-04
WO2020262114A1 (ja) 2020-12-30
JPWO2020262114A1 (pt) 2020-12-30

Similar Documents

Publication Publication Date Title
BR112022012891A2 (pt) Instrumento cirúrgico compreendendo sistema de detecção
BR112021026551A2 (pt) Ativador de função mitocondrial
CL2021000039A1 (es) Moléculas de anticuerpo que se unen a cd73 y usos de las mismas (divisional solicitud 201903796)
BR112015015642A2 (pt) método para personalizar um modo de cena de um dispositivo inteligente
BR112016024163A2 (pt) trava de segurança de captura de agulha para catéter
BR112016029080A2 (pt) sistemas de travamento de fechamento para instrumentos cirúrgicos
BR112017003270A2 (pt) inércia paramétrica e apis
BR112019010115A8 (pt) Método de proporcionar benefícios de higiene bucal
BR112018072454A2 (pt) composição de tratamento de superfície antiferrugem aquosa e membro de metal com superfície revestida
BR112017003730A2 (pt) tubo em camadas
BR112016024773A2 (pt) dispositivo de direcionamento para travamento distal de pinos intramedulares e métodos de uso
BR112018071792A2 (pt) robô móvel com capacidades de movimento equilibrado e de comportamento melhoradas
BR112018007395A2 (pt) 2,4-di-hidróxi-nicotinamidas como agonistas de apj
BR112018003178A2 (pt) absorvente feminino com braçadeiras de barreira
BR112016006428A2 (pt) anticorpo, fragmento de ligação a antígeno do anticorpo, composição farmacêutica, métodos para tratamento e/ou profilaxia de infecção por pseudomona e para produzir um anticorpo, agente de diagnóstico para infecção por pseudomona, kit de detecção para pseudomonas aeruginosa, polinucleotídeo, vetor, e, célula hospedeira transformada
BR112016001699A2 (pt) sistemas de exibição de projetor tendo direcionamento de feixe de espelho não mecânico
BR112019024785A2 (pt) composto de bifenila ou sal do mesmo, composição farmacêutica, agente antineoplásico e uso
BR112017023574A2 (pt) dispositivo de segurança para seringas pré-cheias
BR112019004990A2 (pt) anticorpo que se liga especificamente a il-17a e fragmento funcional do mesmo
BR112016030088A2 (pt) sistema para uma máquina de escavação
BR112019007446A2 (pt) agente desodorante compreendendo neodecanoato de zinco
CL2019002873A1 (es) Moduladores del receptor x del hígado (lxr).
BR112017025639A2 (pt) brinquedo de transformação
BR112017015285A2 (pt) dispositivo de fixação transcraniano para pelo menos um cateter de drenagem
BR112019005759A2 (pt) processamento de imagem em um veículo autônomo não tripulado

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]